BridgeBio Receives U.S. FDA Fast Track Designation for BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer

JTheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (BBOT' or the 'Company), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, reported that the U.S. Food and Drug Administration (FDA) has granted Fast [...]